Site Editor
Gregory J. Riely, MD, PhD
Gregory J. Riely, MD, PhD
Posted: Tuesday, September 3, 2024
A study published in the Journal of Clinical Oncology highlighted findings following investigation of the efficacy and safety of the novel MET inhibitor vebreltinib in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring the MET exon 14 skipping mutation. Yi-Long Wu, MD, of Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China, and colleagues reported the objective response rate was 75%, and the disease control rate was 96.2%.
A total of 52 patients were enrolled in cohort 1 of this multicenter, open-label, single-arm, phase II KUNPENG trial. A total of 35 patients (67.3%) were treatment-naive at the time of enrollment. All patients had c-MET–dysregulated, locally advanced or metastatic NSCLC and the MET exon 14 skipping mutation with no previous MET inhibitors. Participants were administered vebreltinib at a dosage of 200 mg twice a day in 28-day cycles, and the primary endpoint was objective response rate. The secondary endpoint was duration of response.
Efficacy findings revealed an objective response rate of 77.1% (95% confidence interval [CI] = 59.9%–89.6%) in treatment-naive patients vs 70.6% (95% CI = 44.0%–89.7%) in patients with previous treatments. The median duration of response was 15.9 months, the median progression-free survival was 14.1 months, and the median overall survival was 20.7 months. Safety analyses revealed that the most common treatment-related adverse events were peripheral edema (82.7%), QT prolongation (30.8%), and elevated serum creatinine levels (28.8%).
“These results, showcasing promising efficacy in both treatment-naive and previously treated patient populations, position vebreltinib as a promising candidate in the therapeutic landscape of NSCLC,” the investigators concluded.
Disclosure: For full disclosures of the study authors, visit coi.ascopubs.org.
JNCCN Spotlights
